RSS

Phase II

Biotechnology company, Bavarian Nordic, has revealed positive data from the extension study of its Phase II study investigating its universal respiratory syncytial virus (RSV) vaccine, MVA-BN RSV, in older adults. more

News

Genentech has unveiled positive results from its Phase II LADDER study, which evaluated the efficacy and safety of its investigational Port Delivery System with ranibizumab (PDS) in people with wet age-related macular degeneration (AMD). more

News

Positive topline results from the Phase II clinical study assessing an anti-amyloid beta protofibril antibody in patients with early Alzheimer’s disease have been revealed by Eisai and Biogen. more

News

The European initiation of a Phase II clinical trial studying the effectiveness of tumour infiltrating lymphocytes (TIL) therapy in the treatment of patients with metastatic melanoma has been announced by Sarah Cannon Research Institute — UK. more

News

The first European approval for a Phase II clinical trial with THN102 in Parkinson’s patients has been announced by biopharmaceutical company, Theranexus. more

News

A Phase II clinical trial has begun in the US to evaluate a new drug, GDC-0084, that targets the signalling pathway implicated in almost all (90%) of glioblastoma multiforme brain cancer cases. more

News

Lundbeck has signed a definitive agreement to acquire biopharma company, Prexton Therapeutics, obtaining the global rights for foliglurax — a treatment for Parkinson’s that has recently entered clinical Phase II testing. more

News

After the successful completion of the Phase I trial, Araclon Biotech and TFS International have announced a continuation of their partnership to advance the trial of the Alzheimer’s disease (AD) vaccine ABvac40 into Phase II. more

News

Following the publication of Phase II trial data, Futura Medical announces encouraging results, significant improvements in erectile function scores and a favourable safety profile with its topical drug, MED2005. more

Technology

International contract development and manufacturing organisation (CDMO), Hovione has announced the enrolment of the first patient in the Phase II clinical trial of its topical minocycline (HY01) in moderate to severe papulopustular rosacea patients. more

News

Sanofi and Regeneron Pharmaceuticals have revealed positive results from a Phase II investigational study of dupilumab, for the treatment of adults with moderate-to-severe eosinophilic oesophagitis. more

News

Genmab has announced that its collaboration partner for daratumumab, Janssen Biotech, has decided to not initiate stage 2 of the Phase II study. more

News

XEN-D0103 is a potent and selective oral modulator of the cardiac potassium channel Kv1.5 more

The milestone is a result of Avanir initiating dosing in a Phase II clinical trial with AVP-786 for the adjunctive treatment of major depressive disorder. more

All of the 39 investigation sites across seven European countries (Belgium, Finland, France, Germany, the Netherlands, Spain and the UK) are fully operational. more

XEN-D0501, a potent and selective small molecule inhibitor of TRPV1, has successfully completed multiple Phase I studies and been shown to be safe and well tolerated. more